Aker Biomarine AS (AKBM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aker Biomarine AS (AKBM) has a cash flow conversion efficiency ratio of -0.046x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-6.90 Million ≈ $-726.08K USD) by net assets (Nkr149.50 Million ≈ $15.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AKBM equity to assets ratio to measure how much of total assets are equity-financed.
Aker Biomarine AS - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Aker Biomarine AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Aker Biomarine AS to evaluate the quality of earnings relative to operating cash generation.
Aker Biomarine AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aker Biomarine AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LAMDA Development S.A.
AT:LAMDA
|
-0.046x |
|
CJ Korea Express
KO:000120
|
0.050x |
|
Ningbo Kbe Electrical Technology Co
SHE:300863
|
-0.029x |
|
Shandong Head Co Ltd
SHE:002810
|
0.027x |
|
Beijing Kingee Culture Development Co Ltd
SHE:002721
|
0.000x |
|
Henan Yicheng New Energy Co Ltd
SHE:300080
|
-0.019x |
|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
0.083x |
|
CATARC Automotive Proving Ground Co.Ltd.
SHE:301215
|
N/A |
Annual Cash Flow Conversion Efficiency for Aker Biomarine AS (2016–2024)
The table below shows the annual cash flow conversion efficiency of Aker Biomarine AS from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Aker Biomarine AS market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr173.90 Million ≈ $18.30 Million |
Nkr12.20 Million ≈ $1.28 Million |
0.070x | -45.76% |
| 2023-12-31 | Nkr366.50 Million ≈ $38.57 Million |
Nkr47.40 Million ≈ $4.99 Million |
0.129x | +224.36% |
| 2022-12-31 | Nkr378.70 Million ≈ $39.85 Million |
Nkr15.10 Million ≈ $1.59 Million |
0.040x | +1925.77% |
| 2021-12-31 | Nkr370.37 Million ≈ $38.97 Million |
Nkr729.00K ≈ $76.71K |
0.002x | +101.44% |
| 2020-12-31 | Nkr373.17 Million ≈ $39.27 Million |
Nkr-51.04 Million ≈ $-5.37 Million |
-0.137x | -271.77% |
| 2019-12-31 | Nkr154.55 Million ≈ $16.26 Million |
Nkr12.31 Million ≈ $1.30 Million |
0.080x | +80.36% |
| 2018-12-31 | Nkr178.81 Million ≈ $18.82 Million |
Nkr7.89 Million ≈ $830.78K |
0.044x | -71.46% |
| 2017-12-31 | Nkr59.30 Million ≈ $6.24 Million |
Nkr9.17 Million ≈ $965.37K |
0.155x | -45.15% |
| 2016-12-31 | Nkr74.03 Million ≈ $7.79 Million |
Nkr20.88 Million ≈ $2.20 Million |
0.282x | -- |
About Aker Biomarine AS
Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LY… Read more